GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (OTCPK:EPGNF) » Definitions » Beneish M-Score

Epigenomics AG (Epigenomics AG) Beneish M-Score : 24.58 (As of May. 16, 2024)


View and export this data going back to . Start your Free Trial

What is Epigenomics AG Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 24.58 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Epigenomics AG's Beneish M-Score or its related term are showing as below:

EPGNF' s Beneish M-Score Range Over the Past 10 Years
Min: -6.88   Med: -2.62   Max: 48.63
Current: 24.58

During the past 13 years, the highest Beneish M-Score of Epigenomics AG was 48.63. The lowest was -6.88. And the median was -2.62.


Epigenomics AG Beneish M-Score Historical Data

The historical data trend for Epigenomics AG's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG Beneish M-Score Chart

Epigenomics AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.46 -4.88 -1.59 2.58 39.14

Epigenomics AG Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.05 -4.83 39.14 48.63 24.58

Competitive Comparison of Epigenomics AG's Beneish M-Score

For the Diagnostics & Research subindustry, Epigenomics AG's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Epigenomics AG's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Epigenomics AG's Beneish M-Score falls into.



Epigenomics AG Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Epigenomics AG for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 45.3328+0.528 * 1.278+0.404 * 2.9432+0.892 * 0.0642+0.115 * 0.2169
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 21.4693+4.679 * -0.887284-0.327 * 2.8457
=30.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun23) TTM:Last Year (Jun22) TTM:
Total Receivables was $0.23 Mil.
Revenue was 0.076 + 0.143 + 0.105 + 0.144 = $0.47 Mil.
Gross Profit was 0.07 + 0.103 + 0.077 + 0.108 = $0.36 Mil.
Total Current Assets was $4.50 Mil.
Total Assets was $4.57 Mil.
Property, Plant and Equipment(Net PPE) was $0.01 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.37 Mil.
Selling, General, & Admin. Expense(SGA) was $6.50 Mil.
Total Current Liabilities was $2.33 Mil.
Long-Term Debt & Capital Lease Obligation was $0.13 Mil.
Net Income was -2.853 + -5.986 + -6.892 + -1.545 = $-17.28 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0.00 Mil.
Cash Flow from Operations was -3.442 + -3.514 + -3.808 + -2.458 = $-13.22 Mil.
Total Receivables was $0.08 Mil.
Revenue was 0.133 + 0.127 + 0.205 + 6.822 = $7.29 Mil.
Gross Profit was 0.1 + 0.098 + 0.155 + 6.771 = $7.12 Mil.
Total Current Assets was $19.84 Mil.
Total Assets was $21.80 Mil.
Property, Plant and Equipment(Net PPE) was $1.86 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.51 Mil.
Selling, General, & Admin. Expense(SGA) was $4.72 Mil.
Total Current Liabilities was $3.40 Mil.
Long-Term Debt & Capital Lease Obligation was $0.73 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.23 / 0.468) / (0.079 / 7.287)
=0.491453 / 0.010841
=45.3328

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(7.124 / 7.287) / (0.358 / 0.468)
=0.977631 / 0.764957
=1.278

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (4.504 + 0.007) / 4.569) / (1 - (19.84 + 1.863) / 21.797)
=0.012694 / 0.004313
=2.9432

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.468 / 7.287
=0.0642

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.514 / (0.514 + 1.863)) / (2.37 / (2.37 + 0.007))
=0.216239 / 0.997055
=0.2169

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(6.504 / 0.468) / (4.717 / 7.287)
=13.897436 / 0.647317
=21.4693

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.134 + 2.329) / 4.569) / ((0.732 + 3.397) / 21.797)
=0.539068 / 0.18943
=2.8457

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-17.276 - 0 - -13.222) / 4.569
=-0.887284

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Epigenomics AG has a M-score of 30.04 signals that the company is likely to be a manipulator.


Epigenomics AG Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Epigenomics AG (Epigenomics AG) Business Description

Traded in Other Exchanges
Address
Geneststrasse 5, Berlin, BB, DEU, 10829
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.

Epigenomics AG (Epigenomics AG) Headlines